Evaluation of changes in the expression pattern of EDIL3 in different grades of endometrial cancer Subtitle: EDIL3 in endometrial cancer.

CONCLUSION: In our study, we demonstrated overexpression of EDIL3 protein in endometrial cancer. Differences in expression between degrees of tumor differentiation suggest the potential of using changes in EDIL3 level as a new complementary diagnostic marker and target for anti-angiogenic therapy. PMID: 30961491 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/30961491?dopt=Abstract

Source: Current Pharmaceutical Biotechnology - April 7, 2019 Category: Biotechnology Authors: Oplawski M, Dziobek K, Zmarzły N, Grabarek B, Tomala B, Leśniak E, Adwent I, Januszyk P, Januszyk K, Dąbruś D, Boroń D Tags: Curr Pharm Biotechnol Source Type: research